Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 30;7(3):100477. doi: 10.1016/j.esmoop.2022.100477

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Pfizer, The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Median time to definitive deterioration^a,bin EORTC for encorafenib plus cetuximab with or without binimetinib compared with control: (A) Physical functioning; (B) emotional functioning; (C) social functioning. Probability (%) of median time to definitive 10% deterioration in EORTC global health status subscales (A) physical functioning, (B) emotional functioning, and (C) social functioning for patients treated with encorafenib plus cetuximab with or without binimetinib (triplet and doublet, respectively) compared with the control. CI, confidence interval; HR, hazard ratio; EORTC, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.^aDefinitive deterioration is at least 10% worsening relative to baseline with no later improvement above this threshold, or death due to any cause. ^bStratified by Eastern Cooperative Oncology Group performance status, source of cetuximab, and prior irinotecan use at randomization.

Median time to definitive deterioration^a,bin EORTC for encorafenib plus cetuximab with or without binimetinib compared with control: (A) Physical functioning; (B) emotional functioning; (C) social functioning. Probability (%) of median time to definitive 10% deterioration in EORTC global health status subscales (A) physical functioning, (B) emotional functioning, and (C) social functioning for patients treated with encorafenib plus cetuximab with or without binimetinib (triplet and doublet, respectively) compared with the control. CI, confidence interval; HR, hazard ratio; EORTC, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.^aDefinitive deterioration is at least 10% worsening relative to baseline with no later improvement above this threshold, or death due to any cause. ^bStratified by Eastern Cooperative Oncology Group performance status, source of cetuximab, and prior irinotecan use at randomization.